RxDoctor Payments Data

Paul Lee, MD

Interventional Pain Medicine · Fullerton, CANPI 1003078981

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.1% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Medtronic at 56.1% of the total. Reporting peaked in 2023 at $2,633 and has fallen 77.7% since, to $587 in 2025.

$7,686in general payments, 2019–2025

Across 142 payments — averaging $54.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$718
  • Nalu Medical, Inc.$556
  • Abbott$502
  • Merz North America, Inc.$304
  • Merz Pharmaceuticals, LLC$287
  • plus $1K from 12 others

What the payments were for

  • Travel & lodging$76010%
  • Food & beverage$6,92690%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,686 in reported general payments places this provider in the 70th percentile of 188 interventional pain medicine providers in California.

See all interventional pain medicine providers in California

Medicare billing

Part B allowed, 2024
$227,099
Medicare patients
422
Services billed
2,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate25$11,358
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen142$2,370
Gabapentin119$1,737
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen67$1,028
Baclofen58$774
Morphine Sulfate ErMorphine Sulfate37$599
Oxycodone Hcl33$510
Pregabalin37$283
Diclofenac Sodium11$262
Acetaminophen-CodeineAcetaminophen With Codeine25$255
Tramadol Hcl40$184
Cyclobenzaprine Hcl23$159
Tizanidine Hcl21$154
Celecoxib25$145
Meloxicam33$115

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Fullerton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →